Volume 1.21 | Sep 14

Pancreatic Cell News 1.21, September 14, 2010.


Scientists Make Significant Type 2 Diabetes Breakthrough  ShareThis
Scientists have found that the peptide hormone, islet amyloid polypeptide, which gets deposited in the pancreas in type 2 diabetes, is the trigger for a protein complex called the inflammasome. [Press release from Trinity College Dublin discussing online prepublication in Nature Immunology]

Read the Review  
Stress-Free Isolation of Highly Purified Mouse CD4+ T Cells
with EasySep®


‘Key Player’ Genes Indentified That Could Lead to Type 1 Diabetes
Scientists published new research identifying an entire network of genes associated with type 1 diabetes. [Press release from Diabetes UK discussing online prepublication in Nature]

Research Could Lead to More Effective Pancreatic Cancer Treatment
An international trial has shown a commonly used chemotherapy drug is as effective at helping prevent pancreatic cancer returning after surgery as the more expensive standard chemotherapy treatment. [Press release from the University of Liverpool discussing online prepublication in the Journal of the American Medical Association]

LC-MS Reveals Differences Between Primary and Metastatic Pancreatic Cancer Cells
Metastatic pancreatic cancer cells significantly differ from those which develop in the organ itself, analysis with liquid chromatography and tandem mass spectrometry (LC-MS) reveals. [Press release from Chromatography Today discussing online prepublication in the Journal of Biomedical Science]

MesenCult®-XF Medium  
Culture Human Mesenchymal Stem Cells in
Serum-Free MesenCult®-XF

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


A Trans-Acting Locus Regulates an Anti-Viral Expression Network and Type 1 Diabetes Risk
Data implicate IRF7 network genes and their regulatory locus in the pathogenesis of type 1 diabetes. [Nature]

Activation of the NLRP3 Inflammasome by Islet Amyloid Polypeptide Provides a Mechanism for Enhanced IL-1Beta in Type 2 Diabetes
Findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by islet amyloid polypeptide. [Nat Immunol]

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and from Human Islets
Studies characterize the insulinotropic effects of an early-stage, small molecule glucagon-like peptide-1 receptor agonist and provide compelling evidence to support pharmaceutical optimization. [Diabetes]

A High Throughput Micro-Array System of Polymer Surfaces for the Manipulation of Primary Pancreatic Islet Cells
A micro-arrayed library with 496 different polymers was synthesized and used to examine attachment and insulin expression of islet cells. [Biomaterials]

Glucose and Aging Control the Quiescence Period That Follows Pancreatic Beta Cell Replication
Results demonstrate that beta cells quickly regain their capacity to re-enter the cell cycle post-mitosis and implicate glucose control of cyclin D2 expression in the regulation of this process. [Development]

Conditional Ablation of Gsk-3Beta in Islet Beta Cells Results in Expanded Mass and Resistance to Fat Feeding-Induced Diabetes in Mice
Results are consistent with a mechanism whereby endogenous glycogen synthase kinase 3beta (GSK-3beta) activity controls islet beta cell growth by feedback inhibition of the insulin receptor/PI3K/Akt signaling pathway. [Diabetologia]


Adjuvant Chemotherapy with Fluorouracil Plus Folinic Acid versus Gemcitabine Following Pancreatic Cancer Resection
Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved overall survival in patients with completely resected pancreatic cancer. [JAMA]

Survival Benefit with Proapoptotic Molecular and Pathologic Responses from Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
Results have encouraged development of an ongoing Phase II clinical trial aimed to evaluate the efficacy of this treatment regimen in human neuroendocrine tumors. [J Clin Oncol]

Autophagy in Pancreatic Cancer: An Emerging Mechanism of Cell Death
The study reveals that triptolide kills diverse types of pancreatic cancer cells by two different pathways; it induces caspase-dependent apoptotic death in some cell lines and death via a caspase-independent autophagic pathway in the other cell lines tested. [Autophagy]

Membrane Proteomic Analysis of Pancreatic Cancer Cells
Researchers sought to characterize the membrane proteomes of pancreatic ductal adenocarcinoma cells of primary and metastatic origins, and to identify potential target proteins related to metastasis of pancreatic cancer. [J Biomed Sci]


STEMSOFT® Software Inc. Licenses StemLab® Software to Arizona’s Celebration Stem Cell Centre
STEMSOFT Software Inc., the leading provider of software solutions for the cell therapy and transplant community, is pleased to announce the licensing of StemLab, the leading cell therapy and cord blood banking laboratory software, to the Celebration Stem Cell Centre in Gilbert, Arizona. [STEMSOFT Software Inc. Press Release]

AstraZeneca and UCL Join Forces in Sight-Related Stem Cell Medicine
AstraZeneca and University College London (UCL) have entered into a collaboration to develop regenerative medicines for diabetic retinopathy. [University College London Press Release]

The Pancreatic Cancer Action Network and AACR to Award Nearly $3 Million in Pancreatic Cancer Research Grants
The American Association for Cancer Research in partnership with the Pancreatic Cancer Action Network is now accepting applications for the 2011 research grants program. [American Association for Cancer Research Press Release]

Forbion Capital Partners Raises EUR190 Million for New Investments
Forbion Capital Partners, a leading investment firm dedicated to the life science sector, announced the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than EUR190 million ($240 million). [Forbion Capital Partners Press Release]

Lilly to Invest Up to $150 Million in Venture Capital
Eli Lilly & Co., facing competition from cheaper copies of its top-selling drug next year, plans to invest as much as $150 million in three venture capital funds to aid development of new medicines. [Bloomberg]

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET
Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET® (bromocriptine mesylate) tablets in the U.S. [Santarus Inc. Press Release]

After Adverse Effects, Roche Ends Trials of Diabetes Drug
Roche has ended late-stage clinical trials that involved giving patients its experimental diabetes treatment taspoglutide. [American Diabetes Association Press Release]


Appeals Court Stays Stem Cell Injunction
A federal appeals court stayed, or suspended, a preliminary injunction issued two weeks ago that brought federal funding for human embryonic stem cell research to a standstill. [Court of Appeals, United States]
NIH Rushes to Hand Out Stem Cell Grants During Temporary Stay
The National Institutes of Health (NIH) is scrambling to push out research grants for work on human embryonic stem cells (hESCs) and has given a cautious all-clear to in-house stem cell researchers after an appeals court yesterday temporarily lifted a ban on federal funding for hESC research. [National Institutes of Health, United States]
NIH Expands Network Focused on How Genes Affect Drug Responses
The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network, a nationwide collaborative of scientists focused on understanding how genes affect a person’s response to medicines. [National Institutes of Health, United States]
Funds Awarded for Disease Demonstration Studies and Technology Development
The National Institutes of Health announced it has awarded approximately $42 million to expand the scope of eight demonstration projects designed to link changes in the human microbiome to health and disease. [National Institutes of Health, United States]
‘Sound Science’ Code Draws Fire
The first draft policy on scientific integrity from a federal agency, released by the Department of the Interior, has drawn a storm of criticism from watchdogs including the Union of Concerned Scientists, based in Cambridge, Massachusetts. [Union of Concerned Scientists, United States]

Diabetes – Liraglutide: Final Appraisal Determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination on liraglutide for the treatment of type 2 diabetes mellitus and submitted it to the Institute. [National Institute for Health and Clinical Excellence, United Kingdom]
European Medicines Agency Update on Ongoing Benefit-Risk Review of Avandia, Avandamet and Avaglim
The European Medicines Agency is currently reviewing rosiglitazone to determine the impact of new data from recent publications on the risk of cardiovascular problems on the benefit- risk profile of these medicines. [European Medicines Agency, European Union]

New Animal-Research Regulations for the European Union
European scientists will use fewer animals in research when newly approved regulations come into effect across the European Union. [European Parliament, European Union]

NIH Statement Regarding Stay of Stem Cell Injunction [National Institutes of Health, United States]
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings (FR Doc. 2010-22527) [National Institutes of Health, United States]
Participation of National Institute of Diabetes and Digestive and Kidney Diseases on PAR-10-266, Support of NIGMS Program Project Grants (P01) (NOT-DK-10-012) [National Institute of Diabetes and Digestive and Kidney Diseases, United States]
National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting (FR Doc. 2010-22327) [National Institutes of Health, United States]
National Center for Research Resources; Notice of Closed Meetings (FR Doc. 2010-22529) [National Institutes of Health, United States]
Enhancing Peer Review:  Reminder of and Correction to Previous Notice on A2 Resubmission Opportunities for Eligible Applications (NOT-OD-10-135) [National Institutes of Health, United States]
Notice of Correction to RFA-AG-11-010, Basic Research on Self-Regulation (R21) (NOT-AG-10-011) [National Institutes of Health, United States]
Public Meeting on Animal Models–Essential Elements to Address Efficacy Under the Animal Rule; and Reopening of Comment Period (Docket No. FDA-2009-D-0007) [Food and Drug Administration, United States] 

EVENTS (Listed by Date)

NEW Third Annual Maryland Stem Cell Research Symposium
September 22, 2010
Gaithersburg, United States

Annual Human Proteome Organization (HUPO) World Congress
September 19-23, 2010
Sydney, Australia

46th European Association for the Study of Diabetes Annual Meeting
September 20-24, 2010
Stockholm, Sweden

Institute of Medicine – University of Illinois at Chicago Midwest Conference on Diabetes and Obesity
September 21, 2010
Chicago, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

Fraunhofer Life Science Symposium 2010
October 29-30, 2010
Leipzig, Germany

2010 American Pancreatic Association (APA) Annual Meeting
November 3-6, 2010
Chicago, United States

Select Biosciences International Forum on Stem Cells
November 12-13, 2010
Tianjin, China

Australasian Pancreatic Club Annual Meeting
November 15-16, 2010
Melbourne, Australia

Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction
January 12-17, 2011
Keystone, United States

2011 Gastrointestinal Cancers Symposium
January 20-22, 2011
San Francisco, United States

Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

Select Biosciences 5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, DC, United States

Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club
February 10-13, 2011
Maradu, India

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.



Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
here  to post your career opportunities.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Pancreatic Cell News: Archives | Events | Contact Us